metastasis but is also necessary for the natural healing process after ischemic injury [1] . The α v β 3 integrin is a wellknown protein target chosen for designing diagnostic and therapeutic agents aimed at tumor angiogenesis because it is highly expressed only in activated endothelial cells (ECs) of tumor neovasculature and not on normal cells or quiescent ECs [2] . Radiolabeled RGD (Arg-Gly-Asp) peptides and analogs have been specifically pursued for visualizing and quantifying α v β 3 integrin expression noninvasively in tumors with positron emission tomography (PET) [3] [4] [5] . Fluorine-18 is a popular radioisotope for labeling small molecules and peptides because of its well-suited physical half-life (109.7 min) for routine clinical use. Therefore, a number of 18 F-labeled RGD-peptides including [ 18 F]-galacto-RGD [6] and [ 18 F]-AH111585 [7] has been developed for PET imaging of α v β 3 integrin in the last few years. Both of these radiotracers, based on monomeric cyclic RGD-peptides, are under clinical investigation in cancer patients [8, 9] . Although the 18 F-labeled RGD monomer analogs can specifically bind to integrin α v β 3 expressed on the surface of some cancer cells, they have been somewhat limited due to the relatively low receptor-binding affinity and consequently low tumor uptake. In order to enhance the efficiency of tumor targeting and to obtain better in vivo imaging properties, the polyvalency effect was applied to develop multimeric RGD peptides. In our earlier studies with these multimeric peptides, we demonstrated that the receptorbinding affinity and tumor uptake of RGD peptides followed the order of octamer 9 tetramer 9 dimer 9 monomer [10] [11] [12] [13] . The tetrameric and octameric RGD peptides possess higher receptor-binding affinity and higher tumor uptake than their dimeric and monomeric counterparts; however, the consequential higher background signals from tetrameric and octameric RGD peptides especially in the kidneys gave way to choose the more favorable dimeric scaffold for the RGD peptide. In addition, the insertion of the glycine-glycine-glycine (Gly 3 ) or 15-amino-4,7,10,13-tetraoxapentadecanoic acid (PEG 4 ) spacers was found to significantly increase the distance between the two cyclic RGD peptide motifs that resulted in an improvement in the in vitro receptor-binding affinity [14] . Therefore, a new 18 2 or P(RGD) 2 , Fig. 1 ) that yielded our first promising results in murine models [15] . Based on these preclinical findings, our aims for this study were to present a reliable, routine and automated radiosynthesis of a new clinical-grade 2 ) and further evaluate this higher purity tracer in both mice and human.
Material and Methods
All chemicals obtained commercially were of analytical grade (Sigma-Aldrich, USA) and used without further purification. H-11-amino-3,6,9-trioxaundecanoic acid (AEEEA)-Glu[cyclo(Arg-GlyAsp-D-Tyr-Lys)] 2 (PEG 3 -c(RGDyK) 2 ) (AEEEA, 99%), was purchased from Peptides International (USA). The cold reference compound, [ 19 F]FPP(RGD) 2 , was synthesized according to our procedure previously reported [15] .
No F]F-Kryptofix-222 complex and allowed to react at 110°C for 10 min. After cooling the reactor down to 40°C, a hydrolysis step was performed by adding 0.1 N potassium hydroxide (KOH) (0.5 mL) into the reactor and heating the alkaline mixture at 90°C for 10 min. A second azeotropic drying step was carried out with MeCN (2 mL) to remove the residual water. Once the hydrolyzed material was obtained, a solution of bis(4-nitrophenyl) carbonate in MeCN (2 mL and 20 mg/mL) was added to the residue and the mixture was heated at 90°C for 20 min. Upon completion of heating, the reaction mixture was diluted with sterile water (1.5 mL) and purified by the first of two semi-preparative HPLC steps for the entire [ The last method is similar to method 2 except a sodium sulfate (Na 2 SO 4 ) cartridge was installed just before 5 mL V-vial as an extra drying step for the eluent.
The conjugation between [ 18 F]NPE and peptide was executed using 2 mg PEG 3 -c(RGDyK) 2 in anhydrous DMSO (200 μL) with DIPEA (40 μL) at 60°C for 20 min and was quenched by adding 5% acetic acid (0.7 mL). The crude [
18 F]FPP(RGD) 2 product was purified with the second semi-preparative HPLC (PEG 3 2 was eluted from the cartridge using ethanol (United States Pharmacopeia, USP, 1 mL) and then saline (9 mL). The formulated saline mixture was sterile-filtered through a sterile Millex GS filter (0.22 μm, 4 mm) directly into a sterile product vial (30-mL size). 2 (50-150 μL) was injected through the tail vein into the circulation of the mice under isoflurane anesthesia (1-3%). After 120 min post-injection, the animals were placed in the microPET scanner and a 3-min static whole body image was obtained. For the microPET image analyses, regions of interest (ROIs, AMIDE.exe.0.9.1) were drawn over the normal tissue and major organs on decay-corrected whole body coronal images. The radioactivity concentration (accumulation) was obtained from the mean value within the multiple ROIs and then converted to percent injected dose/g (%ID/g) or%ID (SUV).
Human Study with Clinical-Grade [ The radiochemistry protocol for making clinical-grade [
18 F]FPP (RGD) 2 was submitted and approved as an exploratory Investigational New Drug (eIND) application by the Food and Drug Administration (FDA). A healthy volunteer (40 year-old female) was recruited and a written informed consent was obtained via an approved protocol from the Stanford University (IRB). On the day of the scan, no specific patient preparation was requested (i.e., fasting and hydration). The volunteer's vital signs (heart rate, pulse oximetry, body temperature, and blood pressure) were monitored at a regular interval throughout the duration of imaging, up to 3 h post-injection using an automated machine. A 12-lead electrocardiogram (ECG) was also obtained at the same frequency and duration. Blood was obtained just prior to tracer injection for labs, as well as throughout the imaging period for time activity curve calculations. On days 1 and 7 after injection, additional vitals and blood samples were obtained to ensure stability of these parameters. Any unusual or adverse patient symptoms were also recorded on the day of imaging as well as during follow-up.
[ 18 F]FPP(RGD) 2 (518 MBq/14 mCi in 6 mL) was injected intravenously into a healthy human volunteer. The subject was scanned on a GE Discovery LS PET/CT scanner (GE Medical Systems, USA) in 2D mode. The volunteer had a total of 4 PET scans and 1 PET/CT scans acquired after tracer injection. The PET only scans were acquired 30, 120, and 180 min post-injection, using six bed positions (whole body scans from the skull base to the mid-thigh), 3-min emission scans, and 1-min transmission scans with a germanium rod source for attenuation correction. The PET/CT scan was acquired 1 h post-injection using a total of 11 bed positions (total body scan from the vertex to the toes) and 3-min emission scans. In this case, the CT transmission data were used for attenuation correction and anatomical localization of the PET information. The images were reconstructed using an ordered subset expectation maximization algorithm and reviewed in the axial, coronal, and sagittal planes. All reconstructions and image analysis used Xeleris software, version X (GE Healthcare Systems, USA).
Results and Discussion

Radiochemistry
All radiochemical yields (RCYs) and specific radioactivities were decay-corrected to end of bombardment as indicated and reported as means ± SD.
The multi-step radiosynthesis of [ 18 F]FPP(RGD) 2 ( Fig. 1 ) was performed in a modified automated apparatus that consisted a modified commercial radiosynthesis module (TRACERlab FX FN , GE Medical Systems) and a custommade module (Fig. 2) . After a total synthesis time of 170 min, [ 18 F]FPP(RGD) 2 was afforded with consistent RCYs (16.9±2.7%; n=8) and specific radioactivity of 114± 72 GBq/μmol (3.08 ± 1.95 Ci/μmol, n=8). The actual amount of carrier mass measured in the final formulated dose (n=8) was 103±83 μg, which is beneath the upper mass limit of the total carrier ([ 19 F]FPP(RGD) 2 ) that can be present in the final administered dose (240 μg). Radiochemical and chemical purities exceeded 99% via QC HPLC analysis. All other QC criteria were met in accordance with USP Chapter 823 [16] . 18 F-Labeled target-specific peptides are generally synthesized by using an 18 F-prosthetic group (synthon) that will form stable chemical bonds on the peptides. A large number of 18 F-synthons have been developed for synthesizing the 18 F-radiolabeled peptides. In our previous preclinical studies [15] 2 . In retrospect, the use of a rotary evaporator with our module setup still posed a challenge for the automation of the radiosynthesis. As a result, MeCN was replaced with Et 2 O for eluting the first C-18 cartridge (Method 2) so by simply using a helium stream to remove the volatile Et 2 O, this favorable change would allow for the removal of the rotary evaporation step. Since Et 2 O is not generally recommended for use in the TRACERlab module, the [ 18 F] NPE SPE purification and subsequent drying steps were implemented into our customized module. Although there was almost no radioactivity loss during the transferring and drying steps of the [
18 F]NPE preparation, low and unreliable coupling yields were still observed (30±35%; n=3). (Table 1) . Since clinical utilization requires stricter quality control (i.e., higher purity of the final product) for the radiotracer when compared with criteria set for preclinical studies, more attention is especially applied to the purification process. Small impurities were observed to be present in the formulated batch when a Vydac 218TP54 C-18 column was originally used in the radiotracer production for preclinical studies. Although these minor impurities did not seem to significantly impact our previous animal studies, these impurities needed to be removed from the formulated batch before the radiotracer could be administered in human. Thus, a different HPLC column, Phenomenex Gemini C-18, was tested to purify the crude [ 18 F]FPP(RGD) 2 mixture and it fortunately provided the clinical-grade tracer in acceptable chemical and radiochemical purities.
Clinical-grade [ 18 F]FPP(RGD) 2 was used for the PET imaging with normal mice and a healthy human subject. Tracer uptake was represented as %ID/g (mouse, Fig. 3 2 are shown in Fig. 3 . As expected, the results obtained using the higher purity tracer was reasonably consistent to our previously reported findings in mice [15] .
No adverse events were monitored in the first human subject during the pilot volunteer study. As required by the FDA, a full assessment including blood pressure, ECG, and blood count were performed for acute toxicity assessment. Initial radioactivity uptake in the lung, liver, and muscle eventually cleared but high uptake was observed in the kidneys and bladder (1.3 and 8.7%ID/g or 10.1 and 32.5% ID, respectively). For the healthy human study, the images (Fig. 4) and SUV (Table 2) show stable uptake primarily in the spleen 9 liver. The radiopharmaceutical cleared through 2 was otherwise absent in the head, neck, thorax, and extremities.
Some important features for any radiotracer are (1) rapid tracer entry into and clearance from specific tissue in a time frame compatible with the radioisotope used; and (2) high specific binding to target(s) of interest with relatively low tracer binding to non-specific targets. A successful tracer should yield a high tumor to background ratio and therefore a relatively low background signal after tracer clearance is ideal. Although the current study did not yet assess the desired high tracer uptake in tumor, it is just as important to show whether the tracer cleared tissues in the time frame consistent with the half-life of fluorine-18 radioisotope, which this study has now demonstrated. The relatively low background in specific tissues such as the lungs and breast may then allow eventual success of this tracer for detecting tumors present in those locations. In addition, a brain tumor with a broken blood-brain-barrier may also allow for brain 
